Citations

Showing 10 of 108119 citations.

Role of angiotensin-converting-enzyme inhibitors in stroke prevention
Fagan, Susan C., Lee, Linda A., Hess, David C.

Mayo Clinic

American Journal of Health-System Pharmacy | February 22, 2019 | Volume: 60 | Issue: 8 | Pages: 788-793

10.1093/ajhp/60.8.788 | PMID 12749165 Get It

Low‐Gradient Severe Mitral Stenosis: Hemodynamic Profiles, Clinical Characteristics, and Outcomes
Sabbagh, Abdallah El , Reddy, Yogesh N.V. , Barros‐Gomes, Sergio , Borlaug, Barry A. , Miranda, William R. , Pislaru, Sorin V. , Pellikka, Patricia A. , Sabbah, Michael S. , Nishimura, Rick , Pellikka, Patricia A , Borlaug, Barry A , Nishimura, Rick A.

Mayo Clinic

Journal of the American Heart Association | February 22, 2019 | Volume: 8 | Issue: 5 | Pages: No page available

10.1161/jaha.118.010736 | PMID 30793648 Get It

Background Optimal management of patients with severe mitral stenosis ( MS ) and low transmitral gradient is incompletely understood. Methods and Results We examined 101 consecutive patients with severe rheumatic MS (mitral valve area ≤1.5 cm 2 ) who underwent balloon valvuloplasty. Low gradient was defined as mean transmitral gradient <10 mm Hg and low flow as stroke volume index ≤35 mL/m 2 by echocardiography. Symptoms and mortality data were collected. Systolic, diastolic, and arterial function were characterized by measuring left ventricular (LV) end‐systolic elastance, LV stiffness constant (β), diastolic capacitance (predicted LV end‐diastolic volume at a common LV filling pressure of 30 mm Hg), and effective arterial elastance. Low gradient (<10 mm Hg) was present in 55 patients, including low flow/low gradient in 11 and normal flow/low gradient in 44 patients, and high gradient was present in 46 patients. Participants with low‐flow/low‐gradient (LG) MS were older with higher rates of atrial fibrillation (64%) and subvalvular thickening, higher afterload, and decreased LV compliance with lower ejection fraction (57±10% versus 65±4% versus 63±6%, P =0.002) but similar end‐systolic elastance compared with patients with normal‐flow/ LG and high‐gradient MS . The normal‐flow/ LG group had larger mitral valve area and lower left atrial pressure by catheterization, as well as favorable long‐term outcomes compared with the low‐flow/ LG and high‐gradient MS group. A total of 40% of patients with LG MS had no symptomatic benefit from valvuloplasty compared with 18% of patients with high‐gradient MS ( P =0.02). Conclusions Presence of low gradient in patients with severe MS was associated with lesser symptomatic benefit from valvuloplasty. In the subset with low stroke volume index, this may be related to independent ventricular‐vascular uncoupling, decreased LV compliance, and high prevalence of atrial fibrillation in addition to intrinsic MS .
Deep Brain Stimulation and Cognitive Outcomes Among Patients With Parkinson’s Disease: A Historical Cohort Study
Hansen, Allison , Kirlin, Kristin A., Limback-Stokin, Martin M. , Roesler, Kimberly, Velgos, Stefanie N., Lyons, Mark , Geda, Yonas E. , Mehta, Shyamal H. , Hansen, Allison L, Krell-Roesch, Janina, Lyons, Mark K, Geda, Yonas E , Krell‐Roesch, Janina

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | February 22, 2019 | Volume: 31 | Issue: 3 | Pages: 196-200

10.1176/appi.neuropsych.18050118 | PMID 30791806 Get It

Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan
Taniguchi, Shinya , Kurosu, Shinsuke , Gillberg, Per‐Göran , Mattsson, Jan P. , Camilleri, Michael , Camilleri, M , Nakajima, Atsushi

Mayo Clinic

Neurogastroenterology & Motility | February 22, 2019 | Volume: 31 | Issue: 5 | Pages: No page available

10.1111/nmo.13571 | PMID 30793431 Get It

AbstractBackgroundIn two phase 3 trials, elobixibat, a locally acting ileal bile acid transporter inhibitor, resolved constipation and was well tolerated in Japanese patients with chronic constipation. We analyzed the efficacy, safety, and impact on quality of life (QOL) of elobixibat in patients with symptomatically more severe constipation in the two phase 3 trials.MethodsThis post hoc analysis of elobixibat treatment outcomes included data from a 2‐week, randomized, placebo‐controlled, phase 3 trial (10 mg/d), and a 52‐week, open‐label trial (5‐15 mg/d) in subgroups with severe constipation defined as ≤2 spontaneous bowel movements (SBMs) and ≤3 Bristol Stool Form Scale score during the second week of the 2‐week run‐in period. We also analyzed the rates of abdominal pain, diarrhea, and QOL in subgroups according to sex, presence of constipation‐predominant irritable bowel syndrome (IBS‐C) and side effects.Key ResultsIn patients with severe constipation, there was significant improvement in the 10 mg elobixibat group compared to the placebo group in change in SBMs from baseline at week 1 (primary endpoint) of the 2‐week trial. The differences between groups were reduced in patients with more severe constipation. Increasing the dose to 15 mg was effective for more severe constipation in improving the number of SBMs per week in the 52‐week trial. Overall, elobixibat was well tolerated and improved QOL scores, irrespective of gender, presence of IBS‐C or side effects.Conclusions & InferencesElobixibat is effective for symptomatically severe constipation, is well tolerated and improves QOL, irrespective of potentially confounding patient characteristics.
Clinical impact of intraoperative electronic health record downtime on surgical patients
Harrison, Andrew M. , Siwani, Rizwan, Pickering, Brian W. , Herasevich, Vitaly , Harrison, Andrew Marc , Herasevich, Vitaly

Mayo Clinic

Journal of the American Medical Informatics Association | February 22, 2019 | Volume: 26 | Issue: 10 | Pages: 928-933

10.1093/jamia/ocz029 | PMID 30946466 Get It

Abstract Objective Despite increased use of electronic health records (EHRs), the clinical impact of system downtime is unknown. Materials and Methods This retrospective matched cohort study evaluated the impact of EHR downtime episodes lasting more than 60 minutes over a 6-year study period. Patients age 18 years or older who underwent surgical procedures at least 60 minutes in duration with an inpatient stay exceeding 24 hours within the study period were eligible for inclusion. Out of 4115 patients exposed to 1 of 176 EHR downtime episodes, 4103 patients were matched to an unexposed cohort in a 1:1 ratio. Multivariable regression analysis, as well as trend analysis for effect of duration of downtime on outcomes, was performed. Results Downtime-exposed patients had operating room duration 1.1 times longer (p &lt; .001) and postoperative length of stay 1.04 times longer (p = .007) compared to unexposed patients. The 30-day mortality rates were similar between these groups (odds ratio 1.26, p &gt; .05). In trend analysis, there was no association between duration of downtime with respect to evaluated outcomes, postoperative length of stay, and 30-day mortality. Conclusion EHR downtime had no impact on 30-day mortality. Potential associations for increased postoperative length of stay and duration of time spent in the operating room were observed among downtime-exposed patients. No trend effect was observed with respect to duration of downtime and postoperative length of stay and 30-day mortality rates.
Computerized pharmacy databases as source of data on antimicrobial prescriptions in children’s hospitals
Harbarth, Stéphan , Levine, Gail L., Jarvis, William R., Goldmann, Donald A., Huskins, W. Charles

Mayo Clinic

American Journal of Health-System Pharmacy | February 22, 2019 | Volume: 58 | Issue: 21 | Pages: 2069-2071

10.1093/ajhp/58.21.2069 | PMID 11715830 Get It

Regulation of the compounding of positron emission tomography drugs
Hung, Joseph C.

Mayo Clinic

American Journal of Health-System Pharmacy | February 22, 2019 | Volume: 58 | Issue: 2 | Pages: 134-139

10.1093/ajhp/58.2.134 | PMID 11202536 Get It

Extended Lateral Orbital Craniotomy: Anatomic Study and Initial Clinical Series of a Novel Minimally Invasive Pterional Approach
Sattur, Mithun G. , Abi-Aad, Karl R., Welz, Matthew E., Aoun, Rami James N. , Krishna, Chandan , Purnell, Chad A. , Alghoul, Mohammed S., Bendok, Bernard R.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 22, 2019 | Volume: 81 | Issue: 01 | Pages: 088-096

10.1055/s-0038-1677470 | PMID 32021755 Get It

Background Of the minimally invasive “keyhole” alternatives to the pterional region, the supraorbital eyebrow approach is the most widely adopted. Yet it can prove disadvantageous when a more direct lateral microsurgical trajectory of attack to the Sylvian fissure and anterior middle fossa are needed. Objective The extended lateral orbital (XLO) approach was designed to be direct and minimally invasive, with the sphenoid ridge at the center of exposure. Methods Five injected cadaver heads were used for anatomic study of the XLO approach. The anatomic course of the frontalis branch of facial nerve was studied in relation to the XLO incision. Following XLO incision, the bone exposure was measured. The intracranial microsurgical exposure was assessed subjectively. Application of the technique in representative clinical operative cases is provided. Results The frontalis nerve was protected in the subgaleal fat pad, with an average minimum distance of 2.3 cm from the XLO incision. The mean calvarial area exposure was 4.95 cm2 and consistently centered on the sphenoid ridge. Excellent access to ipsilateral Sylvian's fissure, perisylvian regions, and supra-/parasellar structures was possible. The main limitations related to exposure of the posterior Sylvian fissure and the expected limitations of microsurgical instrument manipulation from a smaller craniotomy. Conclusions The XLO approach is a minimally invasive keyhole approach to the pterional region that affords a unique lateral trajectory via a craniotomy centered on the sphenoid ridge. Excellent exposure to properly selected lesions is possible. The incision is at a safe distance from the frontalis branch and shows excellent cosmetic healing.
Standardized antiemetic regimens
Perez, Edith A., Perez, Edith A.

Mayo Clinic

American Journal of Health-System Pharmacy | February 21, 2019 | Volume: 54 | Issue: 20 | Pages: 2404-2404

10.1093/ajhp/54.20.2404 | PMID 9347105 Get It

Flap Reconstruction of Gastrointestinal-to-Genitourinary Fistulas: A 20-Year Experience
Oliver, Jeremie D. , Hammoudeh, Ziyad S. , Akhavan, Arya , Tran, Nho V. , Akhavan, Arya A, Oliver, Jeremie D

Mayo Clinic

Journal of Reconstructive Microsurgery | February 21, 2019 | Volume: 35 | Issue: 07 | Pages: 479-484

10.1055/s-0039-1679880 | PMID 30791062 Get It

Background Gastrointestinal-to-genitourinary fistulas may occur secondary to obstetric complications, radiation therapy, cancer without radiation, inflammatory bowel disease, or previous surgery. Flap reconstruction is useful for complex cases refractory to standard techniques, separating the fistula tracts to aid healing. The purpose of this study was to investigate outcomes and risk factors for complications in flap reconstruction of fistulas from several different etiologies performed over a 20-year period. Methods All patients who underwent flap reconstruction between January 1995 and December 2014 were reviewed. Patient demographics, prior treatment failures, surgical indications, and comorbidities were obtained. Operative and postoperative data were collected, including flap type, length of stay, early and late complications, recurrences, and follow-up time. Operative success was defined as definitive treatment of the fistula without recurrence within 6 months. Results There were 59 patients who underwent 66 reconstructions. The overall complication rate was 59.1%. Complications included infection (21%), dehiscence (17%), and partial flap loss (1.5%). Operative success rate was 51.5%. Smoking history (p = 0.021) and body mass index (BMI) > 35 (p = 0.003) were significantly associated with increased likelihood of postoperative complications following flap reconstruction in these patients. Additionally, fistulas due to cancer resections had a higher likelihood of postoperative complications compared with fistulas due to bowel disease or obstetric complications (p = 0.04). Conclusion Flap reconstruction can be successfully used for complex or refractory gastrointestinal-to-genitourinary fistulas. However, considerable complication and recurrence rates were found in this population. Patients with a BMI > 35 and a history of smoking were at greatest risk in this cohort of experiencing postoperative complications.